fluticasone

(redirected from Breo Ellipta)
Also found in: Dictionary.
Related to Breo Ellipta: Advair

fluticasone

 [floo-tik´ah-sōn″]
a steroid antiinflammatory agent, used as the propionate salt topically in treatment of itching or inflammation, intranasally for allergic rhinitis and other inflammatory nasal conditions, and nasal polyps, and by inhalation in treatment of asthma.

fluticasone

/flu·tic·a·sone/ (floo-tik´ah-sōn″) a synthetic corticosteroid used as the propionate salt to treat inflammation in certain dermatoses, allergic rhinitis and other inflammatory nasal conditions, nasal polyps, and asthma.

fluticasone

[floo͡tik′äsōn′]
a steroid antiinflammatory agent, used topically as the propionate salt in treatment of itching or inflammation, intranasally in the treatment of allergic rhinitis and other inflammatory nasal conditions and of nasal polyps, and by inhalation in treatment of asthma.

fluticasone

A CORTICOSTEROID drug used as an inhalant to treat ASTHMA and hay fever. Extensive studies have shown that fluticasone is safe and effective and, in the recommended dosage, does not affect growth in childhood. Brand names are Flixonase (nasal spray), Flixotide (inhaler) and, for external use only, Cutivate. With SALMETEROL it is marketed as Seretide.
References in periodicals archive ?
Xolair (omalizumab; Novartis/Roche): Which brand stands to gain more share by converting Detractors into Promoters, Breo Ellipta, Tudorza, or Xolair?
GlaxoSmithKline, a pharmaceuticals company, and Theravance, a biopharmaceutical company, have received approval for Breo Ellipta in Canada, it was reported on Friday.
L) and Theravance (NasdaqGS:THRX) on Thursday jointly announced the US Food and Drug Administration's (FDA) approval of BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of adults patients with asthma, a chronic lung disease that inflames and narrows the airways.
If approved, GSK plans to market the product as Breo Ellipta.
M2 EQUITYBITES-February 9, 2015-Theravance's asthma NDA BREO ELLIPTA (FF/VI) to be reviewed by the US FDA Advisory Committee
will manage all development and commercial responsibilities under its collaboration with GlaxoSmithKline and associated respiratory royalty revenues from Relvar or Breo Ellipta (fluticasone furoate/vilanterol: FF /VI), Anoro Ellipta (umeclidinium bromide/vilanterol: UMEC /VI) and VI monotherapy.
M2 PHARMA-May 1, 2015-GlaxoSmithKline passes US FDA's approval of BREO ELLIPTA for treating adults with asthma in the US
According to the companies, the sNDA to the US Food and Drug Administration (FDA) includes a fixed dose combination of the inhaled corticosteroid, fluticasone furoate and the long-acting beta2 agonist, vilanterol (FF/VI) as a once-daily treatment for asthma in patients aged 12 years and older, with the brand name of Breo Ellipta.
M2 PHARMA-February 9, 2015-Theravance's asthma NDA BREO ELLIPTA (FF/VI) to be reviewed by the US FDA Advisory Committee
FF/VI 100/25mcg was approved by the US Food and Drug Administration under the brand name Breo Ellipta in May 2013 as a prescription medication for the long-term, once-daily, maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
GlaxoSmithKline (GSK) a pharmaceutical company based in Middlesex, UK, and Theravance, a US-based pharmaceutical company, have announced that Breo Ellipta, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available in US pharmacies, it was reported on Friday.
M2 EQUITYBITES-October 31, 2013-GSKa[euro](tm)s and Theravancea[euro](tm)s BREO ELLIPTA now available in US pharmacies for the treatment of COPD(C)2013 M2 COMMUNICATIONS http://www.